Bristol Myers Squibb Company (NYSE:BMY) Shares Acquired by Vontobel Holding Ltd.

Vontobel Holding Ltd. raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,279,955 shares of the biopharmaceutical company's stock after acquiring an additional 286,145 shares during the quarter. Vontobel Holding Ltd. owned about 0.06% of Bristol Myers Squibb worth $78,064,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Alta Advisers Ltd lifted its stake in Bristol Myers Squibb by 50.4% in the first quarter. Alta Advisers Ltd now owns 10,150 shares of the biopharmaceutical company's stock valued at $619,000 after buying an additional 3,400 shares during the period. Lodestar Private Asset Management LLC lifted its position in shares of Bristol Myers Squibb by 12.0% during the 1st quarter. Lodestar Private Asset Management LLC now owns 5,093 shares of the biopharmaceutical company's stock valued at $311,000 after acquiring an additional 545 shares during the period. Cypress Capital LLC boosted its stake in Bristol Myers Squibb by 1.0% during the first quarter. Cypress Capital LLC now owns 48,067 shares of the biopharmaceutical company's stock worth $2,932,000 after acquiring an additional 479 shares in the last quarter. Benchmark Financial Wealth Advisors LLC grew its holdings in Bristol Myers Squibb by 8.8% in the first quarter. Benchmark Financial Wealth Advisors LLC now owns 22,566 shares of the biopharmaceutical company's stock worth $1,376,000 after purchasing an additional 1,823 shares during the period. Finally, Deseret Mutual Benefit Administrators increased its stake in Bristol Myers Squibb by 9.6% in the first quarter. Deseret Mutual Benefit Administrators now owns 14,313 shares of the biopharmaceutical company's stock valued at $873,000 after purchasing an additional 1,257 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BMY has been the topic of several research reports. UBS Group lowered their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Jefferies Financial Group decreased their target price on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Argus raised Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and a consensus target price of $58.00.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction on Friday, April 25th. The shares were bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.07% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of BMY traded up $1.20 during mid-day trading on Tuesday, hitting $47.49. 21,026,627 shares of the stock were exchanged, compared to its average volume of 12,936,245. The firm has a 50-day moving average of $47.85 and a two-hundred day moving average of $53.84. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The company has a market cap of $96.65 billion, a PE ratio of 17.79, a price-to-earnings-growth ratio of 1.37 and a beta of 0.38. Bristol Myers Squibb Company has a 52-week low of $39.35 and a 52-week high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same period last year, the company posted ($4.40) earnings per share. The company's quarterly revenue was down 5.6% compared to the same quarter last year. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.22%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.